Arcutis Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary

Arcutis Biotherapeutics

27/02/2024 14:31

* Arcutis Biotherapeutics Inc  ARQT.OQ  reported a quarterly
adjusted loss of 72 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-1.18.  The mean expectation of
seven analysts for the quarter was for a loss of 77 cents per
share. Wall Street expected results to range from -96 cents
to -48 cents per share.
    * Revenue rose 356.8% to $13.53 million from a year ago;
analysts
expected $11.34 million. 
    * Arcutis Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 72 cents​.
    * The company reported a quarterly loss of $66.28 million.
    * Arcutis Biotherapeutics Inc shares had risen by 200.0%
this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 3.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Arcutis
Biotherapeutics Inc is $13.50 

This summary was machine generated from LSEG data February 27 at
02:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.77          -0.72          Beat
 Sep. 30 2023      -0.86          -0.73          Beat
 Jun. 30 2023      -1.25          -1.16          Beat
 Mar. 31 2023      -1.28          -1.31          Missed